Navigation Links
UGA researchers discover new method to reduce disease-causing inflammation
Date:6/16/2014

Athens, Ga. Researchers at the University of Georgia report in the Journal of Biological Chemistry that an enzyme known as Tumor Progression Locus 2, or Tpl2, plays a key role in directing and regulating several important components of the body's immune system. Their discovery may one day lead to new treatments for many common autoimmune diseases.

"We know that immune dysfunction plays a serious role in a number of conditions, and we need better methods for controlling chronic inflammation," said Wendy Watford, assistant professor of infectious diseases in UGA's College of Veterinary Medicine and principal investigator for the study. "Our laboratory is searching for ways to disrupt the fundamental cellular processes that cause inflammation and disease."

The human immune system is an extraordinarily complex system of cells, proteins, tissues and organs that, when everything works properly, search out and destroy disease-causing toxins and pathogens like bacteria and viruses. But sometimes it becomes confused, and the microscopic troops that normally attack only invaders turn their weapons on healthy tissues.

The resulting inflammation caused by wayward defense cells is associated with a number of autoimmune diseases and conditions, including diabetes, obesity, depression, heart disease, stroke, respiratory disease and certain cancers.

Watford and her colleagues conducted tests with genetically modified mice lacking the Tpl2 enzyme in which they stimulated the animal's immune system and observed the behavior of several proteins known as chemokine receptors.

Chemokines act like a dispatcher, alerting the immune system's army of white blood cells to potential threats and directing them to problem areas.

The researchers found activity of three chemokine receptorsknown as CCR1, CCR2 and CCR5were reduced in Tpl2 negative mice. With these proteins operating at reduced capacity, fewer of the white blood cells commonly associated with autoimmune disease are able to accumulate at inflamed tissues where they can attack healthy tissue.

While reducing Tpl2 expression may ease the burden of many painful and debilitating disorders, it also weakens the immune system, making it harder for the body to fight off bacteria, viruses, parasites and cancerous cells.

"A number of laboratories throughout the world have researched the inhibition of chemokine receptors as a potential therapy for a variety of disorders," Watford said. "We still face a number of hurdles, but we hope that this may one day serve as the foundation for a new approach to disease treatment."

The research group is planning additional tests using mouse models that mimic the symptoms of rheumatoid arthritis to see if Tpl2 inhibition will reduce inflammation and ease symptoms.

"This is an emerging field," Watford said. "We have a lot of work to do, but many of our preliminary results are promising."


'/>"/>
Contact: Wendy Watford
watfordw@uga.edu
706-542-4585
University of Georgia
Source:Eurekalert

Related medicine news :

1. Ottawa researchers key to new neuromuscular disease care and research network
2. Researchers uncover new insights into developing rapid-acting antidepressant for treatment-resistant depression
3. Broad Institute, MGH researchers chart cellular complexity of brain tumors
4. Researchers uncover common heart drugs link to diabetes
5. Mayo Clinic researchers discover new form of cancer
6. Researchers recast addiction as a manageable disease
7. Mount Sinai researchers identify protein that keeps blood stem cells healthy as they age
8. Berkeley Lab researchers create nanoparticle thin films that self-assemble in 1 minute
9. Study shows health policy researchers lack confidence in social media for communication
10. Researchers at the Gladstone Institutes find novel approach to reactivate latent HIV
11. UO researchers use rhythmic brain activity to track memories in progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
(Date:9/19/2017)... Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, ... tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , PhD, ...
(Date:9/13/2017)... , Sept. 13, 2017   OrthoAtlanta has ... the Atlanta Football Host Committee (AFHC) for the 2018 College ... Jan. 8, 2018, at Mercedes-Benz Stadium in Atlanta, ... of the AFHC "I,m In" campaign, participating in many activities ... ...
Breaking Medicine Technology: